NERV
NASDAQ HealthcareMinerva Neurosciences, Inc - Common Stock
Biotechnology
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
๐ Market Data
| Price | $6.07 |
|---|---|
| Volume | 108,200 |
| Market Cap | 266.12M |
| Beta | -0.210 |
| RSI (14-Day) | 55.9 |
| 200-Day MA | $4.17 |
| 50-Day MA | $6.53 |
| 52-Week High | $12.46 |
| 52-Week Low | $1.30 |
| Forward P/E | -12.65 |
| Price / Book | -1.87 |
๐ฏ Investment Strategy Scores
NERV scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (50/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NERV in your text
Paste any article, transcript, or post โ the tool will extract NERV and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.